Today: October 22, 2018, 4:03 am

Novotech signs Central Lab Services Agreement with Sonic Clinical Trials

Novotech signs Central Lab Services Agreement with Sonic Clinical Trials 2017-06-27 12:51:56
SYDNEY, AUS, June 23, 2017 - (ACN Newswire) - Asia Pacific specialist CRO Novotech announced today it has expanded its business offering to include central lab services through a preferred partnership agreement with Sonic Clinical Trials, an affiliate of international healthcare company, Sonic Healthcare.

Through this unique partnership, Novotech clients will be able to select from a wide menu of assays or biomarkers, access a trial-specific kit assembly service and use a single clinical trial-dedicated laboratory with a global reach, for priority processing of clinical trial samples.

Announcing the new partnership, Novotech CEO Dr. John Moller said, "Novotech has always focused on offering flexible and cost effective clinical trial solutions. Through our partnership with Sonic Clinical Trials, our clients will experience a seamless integration of laboratory services and clinical trial data management by Novotech. From the start to finish, our clients are supported by a team of dedicated project managers.

"Another key benefit to our clients is the fact that Sonic Clinical Trials is pre-audited and an approved Novotech vendor. This removes our clients' need to undertake their own central lab vendor assurance - providing a further savings in cost and clinical trial time."

Sonic Clinical Trials is a registered Research Service Provider (RSP) with AusIndustry, a division of the Australian Government's Department of Industry, Innovation and Science.

"Sonic Clinical Trials' RSP status assists our eligible international clients when accessing the Australian R&D Tax Incentive Scheme. Research from a recent Frost and Sullivan white paper revealed that eligible companies can conduct early stage clinical trials 60% more cheaply in Australia than the USA," explained Dr. Moller.

"Novotech's size and Asia Pacific focus allows our clients to enjoy a direct, hands-on approach to accessing some of the largest patient pools in the world, but we balance this with providing global gold-standard central laboratory services and data management platforms."

About Australian R&D Tax Incentive Scheme

Through the Australian R&D Tax Incentive Scheme, eligible companies may claim a 43.5% R&D tax refund on eligible R&D expenditure. For more information about this scheme, see the joint Novotech / Frost & Sullivan white paper, "Australia: The preferred destination for early phase clinical trials", Mar. 31, 2017.

About Sonic Clinical Trials

Sonic Clinical Trials is a wholly owned subsidiary of Australian-owned Sonic Healthcare, one of the world's largest specialist medical diagnostics companies, employing more than 33,000 people in Australia, New Zealand, the United Kingdom, Germany, Switzerland, Belgium, Ireland and the USA. Sonic Clinical Trials is a registered Research Service Provider (RSP) with AusIndustry which allows it to assist international clients to register for the Australian R&D Tax Incentive Scheme. To learn more, please visit

About Novotech

Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region, while it has worldwide reach through its network of strategic partners.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. For more information, please visit


Digital Mantra Group

Susan Fitzpatrick-Napier

AU: +61 2 8218 2144 / USA: +1 650 798 5238




Justine Lamond

Marketing & Communications Manager

AU: +61 2 8569 1458


Topic: Clinical Trial Results

Sectors: HealthCare

From the Asia Corporate News Network

Copyright © 2017 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Press Information

Published by
ACN Newswire
+65 6304 8926

# 610 Words
Related Articles
More From Health
Net Savings Link, Inc. (OTC: NSAV), a medical technology and software company, announced today that its subsidiary, Shanghai based [..]
Net Savings Link, Inc. (OTC: NSAV), a medical technology and software company, announced today that the Company has acquired a [..]
Drug Abuse Treatment Market to Surpass US$ [..]
(EMAILWIRE.COM, August 06, 2018 ) Global Drug Abuse Treatment Market, by Abuse Type (Alcohol Dependence, Tobacco/Nicotine Addiction, [..]
Nurse Staffing Agency Website Focuses on Services; [..]
Elkhart, IN; August 1, 2018 – Excellent Nursing Services, Inc. (ENS) has announced the launch of the agency’s website highlighting [..]
Primary Sclerosing Cholangitis Market to Reach US$ [..]
(EMAILWIRE.COM, July 30, 2018 ) Global Primary Sclerosing Cholangitis Market, by Drug (BT1023, GS-9674, NGM282, OCA, LUM001, and [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.